K |
Ahmet Baschat
|
US |
Diagnosis and management of placenta based FGR <32 weeks |
K |
Enrico Ferrazzi |
IT |
Haemodynamics in pregnancies with growth restricted fetuses |
O |
Damiano Lo Presti |
IT |
Role of maternal haemodynamic evaluation in the definition of fetuses with growth restriction outcome |
O |
Manel Mendoza |
ES |
Pravastatin to treat early-onset fetal growth restriction |
O |
Jana Brodszki |
SE |
Management of very early onset IUGR. Single center experience 1998-2015 |
O |
Tamara Stampalija |
IT |
Uterine arteries blood flow volume in fetuses with inappropriate growth for gestational age and normal doppler velocimetry |
O |
Andrew Sharp |
UK |
A prediction model for short-term neonatal outcomes in severe early-onset IUGR |
|
Discussion |
|
|
10:10 |
Refreshment Break
|
K |
Francesc Figueras |
ES |
Investigation and management of late onset FGR |
PO |
M Serra |
ES |
Placental findings in small for gestational age and growth restricted fetuses |
O |
Marek Lubusky |
CZ |
Maternal serum levels of PlGF and sFlt-1 in predicting delivery of an SGA newborn |
PO |
Valentina Giardini |
IT |
Placental growth factor (plGF) as a marker of fetal growth restriction (FGR) caused by placental dysfunction: correlation with uterine arteries doppler and placental histology |
PO |
Federica Fusè |
IT |
sFlt-1/PlGF ratio in pregnancies complicated by placental insufficiency |
PO |
Federica Fusè |
IT |
sFlt-1/PlGF ratio and maternal hemodynamics in pregnancies complicated by placental insufficiency |
PO |
Serena Rigano |
IT |
The no man’s land between late IUGR and AGA fetuses: the constitutionally small fetus. |
PO |
Raigam J Martinez-Portilla |
ES |
Higher-risk of adverse perinatal outcome in adequate-for-gestational age fetuses with abnormal cerebro-placental ratio |
PO |
José Morales Rosello |
ES |
Comparison among cerebroplacental ratio, Intergrowth-21st standards, customized growth and local population references for the prediction of fetal compromise. Which is the best approach? |
PO |
José Morales Rosello |
ES |
Is it possible to predict late antepartum stillbirth by means of cerebroplacental ratio and maternal characteristics? |
PO |
Alice Zavatta |
IT |
Is labour induction the right choice in term IUGR fetuses? |
PO |
Eva Meler |
ES |
Perinatal outcomes when electively inducing low fetal weight |
|
Discussion |
|
|
O |
Tullio Ghi |
IT |
The Italian multicentre study |
O |
Katherine Grantz |
US |
The NICHD fetal growth studies on dichorionic twin pairs |
PO |
Mariano Lanna |
IT |
Twin-specific doppler nomograms in uncomplicated monochorionic twins |
|
Discussion |
PO |
Carman Wing Sze Lai |
HK |
Perinatal outcomes among twin with severe growth discordance more than 30% in a 7-year retrospective cohort |
PO |
Mariano Lanna |
IT |
Monochorionic twin pregnancies complicated with twin-twin transfusion syndrome and selective growth restriction of donor twin |
PO |
Mariano Lanna
|
IT |
Perinatal outcome in monochorionic twin pregnancies complicated with selective intrauterine growth restriction
|
12:15 |
Lunch
|
|
O |
Anna David
|
UK |
Scientific rationale and aims of the consortium
|
O |
Rebecca Spencer
|
UK |
Ethical issues in a trial of maternal gene therapy
|
| |
|
Understanding early onset FGR: The EVERREST Prospective study
|
SO |
Kasia Maksym
|
UK |
Outcomes of early onset FGR: the fetus
|
SO |
Francesc Figueras
|
ES |
Early onset FGR - baseline medical and obstetric characteristics: 6 year prospective study
|
SO |
Ingran Lingam
|
UK |
Outcomes of early onset FGR: the neonate at 12 months
|
SO |
Anna David
|
UK |
Pregnant women’s experiences and perceptions of study participation
|
O |
Karel Marsal
|
SE |
Challenges in recruitment in studies of FGR
|
SO |
Tommi Heikura
|
FI |
Reproductive toxicology studies: human placenta and pre-clinical rabbit
|
|
Discussion
|
|
|
|
|
|
Developing and Planning the EVERREST clinical trial
|
SO |
Tommi Heikura
|
FI |
Developing the ATIMP (Advanced Therapy Investigational Medicinal Product) for EVERREST
|
SO |
Robert Shaw
|
UK |
Manufacturing the EVERREST IMP (Investigational Medicinal Product)
|
SO |
Anna David
|
UK |
FGR as an orphan disease
|
SO |
Rebecca Spencer
|
UK |
Inclusion and exclusion criteria and predicting outcome of early onset FGR
|
SO |
Rebecca Spencer
|
UK |
Developing standard maternal and fetal adverse event criteria for FGR clinical trials
|
SO |
Jade Dyer
|
UK |
Regulatory Process - MHRA
|
|
Discussion; Closing Remarks |
|
|
15:50 |
Refreshment Break
|
O |
Wessel Ganzevoort |
NL |
Yes; let's get away from dichotomisation |
O |
Jason Gardosi |
UK |
No; size does matter when assessing growth |
16:30 |
Discussion
|
K |
Lesley McCowan |
NZ |
Overview of international guidelines on fetal growth |
O |
Patrizia Vergani |
IT |
Protocols in Lombardy and Italy |
17:15 |
Plenary / Open Forum
| | General discussion and take home messages
|
18:00 |
Close |